Immuneering Co. (NASDAQ:IMRX) Short Interest Update

Immuneering Co. (NASDAQ:IMRX - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a decline of 6.7% from the September 30th total of 1,630,000 shares. Currently, 7.2% of the shares of the company are sold short. Based on an average trading volume of 6,690,000 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Several analysts recently weighed in on IMRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of Immuneering in a research report on Friday, September 13th. Chardan Capital reduced their price objective on Immuneering from $16.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.60.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd grew its holdings in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after acquiring an additional 9,274 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in shares of Immuneering in the 3rd quarter valued at $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Immuneering in the 2nd quarter worth about $44,000. Acadian Asset Management LLC acquired a new stake in Immuneering during the 2nd quarter worth about $67,000. Finally, Vanguard Group Inc. lifted its stake in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company's stock valued at $3,479,000 after buying an additional 129,851 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Price Performance

Shares of Immuneering stock traded down $0.06 on Thursday, hitting $1.86. The company had a trading volume of 278,288 shares, compared to its average volume of 2,359,758. Immuneering has a 52 week low of $1.00 and a 52 week high of $8.89. The company has a market cap of $55.15 million, a PE ratio of -1.01 and a beta of -0.45. The business has a 50-day simple moving average of $1.99 and a 200-day simple moving average of $1.59.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. On average, equities research analysts predict that Immuneering will post -1.89 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.